Skip to content

Panchgavya Therapy in prophylaxis and as an adjuvant therapy in management of Covid 19.

Prospective, parallel arm, randomized controlled trial to evaluate safety and efficacy of Panchgavya Therapy in prophylaxis and as an adjuvant therapy in management of Covid 19. - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026793
Enrollment
120
Registered
2020-07-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Panchgavya Therapy: Ayurcoronil-1- 15 ml BD (after meals) with warm water. Coripel- 2 drops on mask two times a day. Coronoj- Cotton gauge med wet with Coronoj and placed at nostrils fo

Sponsors

Ionisation Filtration Industries PvtLtd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with RT-PCR confirmed COVID-19 illness. Age of 18-65 years of either sex (Both including) Mild to Moderate Covid 19 disease (NEWS score NMT 7) Signed informed consent. Cases with or without presenting with fever and/or upper respiratory tract illness (Influenza-like illness, ILI). Subjects at high risk of exposure to COVID 19 Health care and frontline workers involved in the treatment of COVID19 cases Family members of COVID19 cases or direct contact

Exclusion criteria

Exclusion criteria: Subjects with any comorbidity which is critical at the screening Allergies, known to be allergic to research drugs Confirmed pneumonia cases with or without symptoms Patients who have participated in other clinical trials within 1 month Proves unfit for the study as a sole discretion of the investigator Being pregnant or breastfeeding Requiring ICU admission at the screening Past History of MI, Epileptic episodes Not giving consent

Design outcomes

Primary

MeasureTime frame
% of subjects with negative RT-PCR for COVID 19 at the end of study Change in clinical symptom presentation in Cough, breathlessness, persistent pain and pressure in the chest, loss of appetite, fatigue on 5 point ordinal scale-None, mild, moderate, severe , extremely severe Clinical status expressed in percentage of subjects reporting each severity rating on a 5-point ordinal scaleTimepoint: 24 hrs. of treatment regimen, patient to be observed daily for till the time of discharge or day 10 whichever is earlier

Secondary

MeasureTime frame
Change in National Early Warning Score (SpO2, respiratory rate, heart rate, fever) Requirement of admission to intensive care unit No. of days of hospitalization Requirement of hospitalizationTimepoint: 24 hrs. of treatment regimen, patient to be observed daily for till the time of discharge or day 10 whichever is earlier

Countries

India

Contacts

Public ContactMr Vivek Joshi

Mprex Healthcare Pvt Ltd

gayatri.mbgindia@gmail.com855491264

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026